The human papillomavirus (HPV) vaccine was introduced in the Philippines in a phased approach in 2015. PATH and the University of the Philippines Manila – National Institutes of Health conducted a retrospective, cross-sectional micro-costing study focused on ongoing HPV vaccination delivery and its operational context across all levels of the health system. Using structured questionnaires and data collection from secondary sources, the weighted mean financial and economic costs per dose of the HPV vaccination program aggregated across all levels of the health system were estimated at US$ 3.72 and US$ 29.74. The activities contributing most significantly to costs were service delivery and vaccine collection or distribution and storage at the health facility and administrative levels, respectively. The opportunity costs for health worker and non-health worker time accounted for 77% of the economic cost per dose.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.